Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

PPAR-δ is a potential modulator of central carbon metabolism in human adipocytes

Sun L., Wabitsch M., Yang J., Sakharkar MK.

Laboratory Study on Systemic / IV, published in Bioinformation (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Bioinformation (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42282358
PMCID
PMC13252273
DOI
10.6026/973206300222419

Abstract (original English)

Adipogenesis involves adipocyte differentiation and synthesis and storage of fats. PPAR-γ is the master regulator of adipogenesis and regulates genes for adipocyte differentiation, lipogenesis, adipocyte survival and adipokine secretion. Central carbon metabolism (CCM) comprises of three key pathways glycolysis, tricarboxylic acid (TCA) cycle and pentose phosphate pathway (PPP). CCM utilizes carbon sources to provide energy and building blocks for lipogenesis. Several targets of transcription factor PPAR-γ have been identified in CCM pathways. However, the exact mechanism of PPAR-γ modulation in adipogenesis via CCM remains elusive. Therefore, it is of interest to evaluate the effects of PPAR-γ on CCM in differentiated human SGBS adipocytes by real time-qPCR and metabolomics using its agonist 15d-PGJ2 and antagonist GW9662. Surprisingly, our results suggest that PPAR-δ rather than PPAR-γ is likely to be the key modulator of CCM in differentiated adipocytes at least under current experimental conditions with both 15d-PGJ2 and GW9662 being PPAR-δ agonists, although PPAR-γ plays a crucial role in adipogenesis and lipogenesis. This data provides insight to manage obesity and diabetes using PPAR-δ agonists. Further studies are warranted to explore the regulation of CCM by PPARs in adipocytes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research